| Diabetes Mellitus, Non-Insulin-Dependent
Basaglar vs Janumet XR
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Basaglar vs Janumet with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJanumet has a higher rate of injection site reactions vs Basaglar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Janumet but not Basaglar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Basaglar
Janumet
At A Glance
SC injection
Once daily
Long-acting insulin analog
Oral
Once daily
DPP-4 inhibitor / biguanide
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Type 1 Diabetes Mellitus Approximately one-third of total daily insulin requirements SC once daily; short- or rapid-acting pre-meal insulin covers the remainder.
Diabetes Mellitus, Non-Insulin-Dependent 0.2 units/kg or up to 10 units SC once daily.
Diabetes Mellitus, Non-Insulin-Dependent Take once daily with a meal; recommended starting dose is 100 mg sitagliptin and 1000 mg metformin HCl extended-release once daily; maximum daily dose is 100 mg sitagliptin and 2000 mg metformin HCl; dose of sitagliptin component limited to 50 mg once daily if eGFR falls below 45 mL/min/1.73 m2; do not split, crush, or chew tablets.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin glargine or any excipient in BASAGLAR
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- History of a serious hypersensitivity reaction to JANUMET XR, sitagliptin, or metformin, such as anaphylaxis or angioedema
Adverse Reactions
Most common (>=5%) Infection, nasopharyngitis, upper respiratory tract infection
Serious Severe hypoglycemia, anaphylaxis, peripheral edema, lipodystrophy, localized cutaneous amyloidosis
Postmarketing Medication errors (accidental administration of rapid-acting insulin instead of insulin glargine), localized cutaneous amyloidosis, hyperglycemia or hypoglycemia associated with injection site changes
Most common (>=5%) Diarrhea, upper respiratory tract infection, headache (from sitagliptin and metformin coadministration studies); nasopharyngitis (sitagliptin monotherapy); hypoglycemia, diarrhea, nausea (extended-release metformin added to glyburide)
Serious Lactic acidosis, pancreatitis, heart failure, acute renal failure, vitamin B12 deficiency, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid
Postmarketing Anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, Stevens-Johnson syndrome, hepatic enzyme elevations, fatal and non-fatal hemorrhagic and necrotizing pancreatitis, worsening renal function including acute renal failure, tubulointerstitial nephritis, severe and disabling arthralgia, bullous pemphigoid, constipation, vomiting, myalgia, rhabdomyolysis, cholestatic and hepatocellular liver injury
Pharmacology
Insulin glargine is a long-acting human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, providing sustained glucose-lowering activity over 24 hours with no pronounced peak.
JANUMET XR combines sitagliptin, a selective DPP-4 inhibitor that slows inactivation of incretin hormones (GLP-1 and GIP) to increase insulin release and decrease glucagon in a glucose-dependent manner, and metformin, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity without altering insulin secretion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Basaglar
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (6/12) · Qty limit (0/12)
Janumet
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Basaglar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Janumet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Basaglar
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Janumet
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Basaglar.
No savings programs available for Janumet.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BasaglarView full Basaglar profile
JanumetView full Janumet profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.